News Article | October 29, 2016
Plancher Orthopaedics & Sports Medicine is pleased to announce that orthopaedic surgeon Dr. Margaret Harvey has joined the practice. Dr. Harvey brings a wealth of experience from her years in the United States Navy where she trained at Walter Reed National Military Medical during Operation Iraqi Freedom and Operation Enduring Freedom, as well as having been stationed in Okinawa, Japan and Camp Lejuene, NC. “We are thrilled to have Dr. Harvey join the group,” noted Dr. Kevin Plancher, founder of Plancher Orthopaedics. “Dr. Harvey brings terrific experience diagnosing and treating a wide variety of orthopaedic injuries and conditions which we believe will be a tremendous asset to her patients and to the community at large.” Dr. Harvey will head up the Women’s Sports Health practice at Plancher Orthopaedics which promotes healthy and injury free sports activity for women who engage in sports such as tennis, skiing, running, swimming, volleyball and much more. She will also treat professional women athletes with the latest techniques in injury prevention and treatment. Dr. Harvey will offer the newest in treatment options, including regenerative stem cell therapy, for a wide range of knee and shoulder injuries along with Dr. Plancher, founder of the Center for Regenerative Medicine at Plancher Orthopaedics. Dr. Harvey accepts Medicare and most insurance plans. Bio: Dr. Margaret Harvey is board certified by the American Board of Orthopedic Surgery. She completed a surgical internship at the National Naval Medical Center in Bethesda, MD, her orthopaedic surgery residency at Walter Reed National Military Medical Center and a sports fellowship at the New England Baptist Hospital in Boston, MA, where she was an assistant team physician for the Boston Celtics. Dr. Harvey was a General Medical Officer with the United States Marine Corps at Camp Foster in Okinawa, Japan as well as a staff orthopaedic surgeon at the United States Naval Hospital in Okinawa, Japan. Most recently, Dr. Harvey treated Marines, Sailors and Marine Corps Special Forces (MARSOC) at the United States Naval Hospital, Camp Lejeune in Jacksonville, North Carolina. Prior to her becoming a physician, she was a physical therapist for five years. In her free time, Dr. Harvey likes to spend time with her family in Wilton, CT and is training for her fourth marathon. Plancher Orthopaedics & Sports Medicine is a general orthopaedics and sports medicine practice with offices in New York City and Greenwich, CT. http://www.plancherortho.com
News Article | December 20, 2016
BOSTON--(BUSINESS WIRE)--New England Baptist Hospital (NEBH), the premier regional provider for orthopedic surgery and the treatment of musculoskeletal diseases and disorders has been named a GE Center of Excellence for hip and knee replacement surgery. With this designation, eligible GE plan members can elect to receive enhanced coverage for their joint replacement surgery at NEBH. As this is a national program, NEBH will support patients whether they live locally in the Boston area or plan to travel to NEBH from out of town. “As value-based health care gains traction, a fresh approach is needed to delivering care that leads to better patient care, quality and outcomes at a lower cost,” said Trish Hannon, president and CEO of NEBH. “As the largest orthopedic hospital in the region, we are excited to partner with GE on this program.” The partnership between NEBH and GE is part of a growing trend where GE and other larger, self-insured companies are choosing to contract directly with high value care providers for specialty care and treatment to provide high quality, cost effective employee health benefits. As part of this partnership, New England Baptist Hospital will offer hip and knee replacement services at a fixed price known as a bundled payment, providing both quality care and value to GE and its employees. “Bundled payments are the future of health care delivery,” said Professor Michael E. Porter, Harvard Business School. “They drive value for patients through supporting care integration, creating accountability for patient outcomes, and rewarding innovation to improve efficiency. Leading employers have been pioneers in embracing this new model, which allows their employees to receive care from excellent providers and control costs. New England Baptist Hospital has taken a big step to position itself for the incoming care delivery model.” NEBH industry recognition includes being named by U.S. News & World Report as one of the top hospitals in the country for orthopedics, and ranked as one of the top 100 women-led businesses in Massachusetts by The Commonwealth Institute and Boston Globe Magazine. NEBH is a 2016 Guardian of Excellence award winner for the ninth consecutive year for outstanding clinical quality and patient experience. About New England Baptist Hospital New England Baptist Hospital (NEBH) is the premier regional provider for orthopedic surgery and the treatment of musculoskeletal diseases and disorders. NEBH has been nationally recognized for high patient satisfaction and leadership in quality and clinical outcomes. The Hospital is committed to improving the health and well-being of those living throughout its community by providing opportunities for people of all ages to be active, stay social and keep moving. NEBH is a teaching affiliate of Tufts University School of Medicine and conducts teaching programs in collaboration with the Harvard School of Public Health and the Harvard Medical School. NEBH is celebrating its 30th year as the official hospital of the Boston Celtics. www.nebh.org
Gurcan H.M.,New England Baptist Hospital |
Keskin D.B.,Dana-Farber Cancer Institute |
Ahmed A.R.,New England Baptist Hospital
Autoimmunity Reviews | Year: 2010
Objective: Intravenous immunoglobulin (IGIV) has provided an essential replacement therapy for primary and secondary immunodeficiencies patients and prophylaxis of infectious diseases in them. It is also used in several autoimmune and chronic inflammatory disorders. An overview of IGIV with information on several commercially available IGIV products is discussed. Data Sources: Medline databases and literature provided by the manufacturer for each product presented in the manuscript. Study Selection: From the vast body of information on IGIV, only those studies were selected that were pertinent to general features of IGIV (as presented below) or information provided by the manufacturer that facilitated comparing one product to the other. Data Extraction: Data was extracted on production, and purification procedures, removal of infectious agents, physical and biochemical properties and issues of safety. Data was extracted only for products available in the US. Data Synthesis: IGIV is prepared using pooled plasma. The purification of IGIV is a complex and multi-step process. There is a reciprocal relationship between the purity of IgG in the product and the recovery rate from the total plasma. It is quite possible that some of the biological mediators of the inflammatory and immune systems may be present in trace amounts. Screening and removal of blood borne pathogens is necessary and there are several different techniques available. The specifics of the administration are often variable and no consistent pattern or protocol has been used. When limited dosages are required IGIV may be administered subcutaneously. The side effects associated with IGIV are usually mild and self-limiting. Conclusion: There are differences in products produced by different manufacturers. The current data does not provide sufficient detail or information to be able to make specific recommendations for the use of a given commercial preparation in a specific disease state. The use of IGIV is associated with certain common and uncommon side effects. The identification of risk factors that might predispose a patient to developing them have been studied and reported. In choosing a IGIV preparation the user may avoid features that may predispose to certain side effects. Equally important is monitoring of patients during and after the IGIV therapy. © 2010 Elsevier B.V. All rights reserved.
Cole B.J.,Rush University Medical Center |
Farr J.,OrthoIndy |
Winalski C.S.,Cleveland Clinic |
Hosea T.,Robert Wood Johnson Medical School |
And 3 more authors.
American Journal of Sports Medicine | Year: 2011
Background: There are currently several approaches being pursued to treat focal defects of articular cartilage, each having specific advantages or challenges. A single-stage procedure that uses autologous cartilage fragments, Cartilage Autograft Implantation System (CAIS), is being evaluated in patients and may offer a clinically effective option. Purpose: To establish the safety of CAIS and to test whether CAIS improves quality of life by using standardized outcomes assessment tools. Study Design: Randomized controlled trial; Level of evidence, 2.Methods: Patients (n = 29) were randomized (1:2) with the intent to treat with either a control (microfracture [MFX]) or an experimental (CAIS) procedure. Patients were followed at predetermined time points for 2 years using several standardized outcomes assessment tools (SF-36, International Knee Documentation Committee [IKDC], Knee injury and Osteoarthritis Outcome Score [KOOS]). Magnetic resonance imaging was performed at baseline, 3 weeks, and 6, 12, and 24 months. Results: Lesion size and International Cartilage Repair Society (ICRS) grade were similar in both groups. General outcome measures (eg, physical component score of the SF-36) indicated an overall improvement in both groups, and no differences in the number of adverse effects were noted in comparisons between the CAIS and MFX groups. The IKDC score of the CAIS group was significantly higher (73.9 ± 14.72 at 12 months and 82.95 ± 14.88 at 24 months) compared with the MFX group (57.78 ± 18.31 at 12 months and 59.5 ± 13.44 at 24 months). Select subdomains (4/5) in the KOOS instrument were significantly different at 12 and 18 months, and all subdomains (Symptoms and Stiffness, Pain, Activities of Daily Living, Sports and Recreation, Knee-related Quality of Life) were significantly increased at 24 months in CAIS with scores of 88.47 ± 11.68, 90.64 ± 7.87, 97.29 ± 3.8, 78.16 ± 22.06, and 69 ± 23.15 compared with 75 ± 9.31, 78.94 ± 13.73, 89.46 ± 8.13, 51.67 ± 26.01, and 37.15 ± 21.67 in the MFX group. These significant improvements were maintained at 24 months in both IKDC and KOOS. Qualitative analysis of the imaging data did not note differences between the 2 groups in fill of the graft bed, tissue integration, or presence of subchondral cysts. Patients treated with MFX had a significantly higher incidence of intralesional osteophyte formation (54% and 70% of total number of lesions treated) at 6 and 12 months when compared with CAIS (8% and 25% of total number of lesions treated).Conclusion: The first clinical experience in using CAIS for treating patients with focal chondral defects indicates that it is a safe, feasible, and effective method that may improve long-term clinical outcomes. © 2011 The Author(s).
Kwon B.,Tufts University |
Kwon B.,New England Baptist Hospital |
Kim D.H.,New England Baptist Hospital
Journal of the American Academy of Orthopaedic Surgeons | Year: 2016
Lateral lumbar interbody fusion is a minimally invasive spinal fusion technique that uses the retroperitoneal approach to the anterior spinal column. Mechanical and technical results of the technique compare favorably with those of anterior lumbar interbody fusion in regard to large graft placement, graft volumes, and early initial stability. Lateral lumbar interbody fusion uses the transpsoas approach and traverses near the lumbar plexus. It is not, however, without its unique complications. Groin pain or numbness is well tolerated and often temporary; however, quadriceps palsy can be long-lasting and debilitating. Rarer but serious complications include vascular and visceral injury. Lateral lumbar interbody fusion has been used successfully to treat common degenerative spinal conditions such as spinal instability, stenosis, scoliosis, and degenerative disk disease. While understanding of the lumbar plexus and the technical challenges of the procedure improves, lateral lumbar interbody fusion will continue to provide safe and successful clinical outcomes with less morbidity than traditional procedures. © 2016 by the American Academy of Orthopaedic Surgeons.
Werner S.D.,New England Baptist Hospital |
Bono J.V.,Tufts University |
Nandi S.,Tufts University |
Ward D.M.,Tufts University |
Talmo C.T.,Tufts University
Journal of Arthroplasty | Year: 2013
Dual-modular femoral stems with exchangeable necks theoretically allow optimization of hip joint biomechanics via selective restoration of femoral anteversion, offset, and limb length. A potential disadvantage is the possible generation of metal ions and debris by fretting and crevice corrosion at the additional stem-neck interface. We present 2 cases of early-onset adverse inflammatory tissue reactions as a result of accelerated corrosion at the stem-neck interface of a dual-modular implant, requiring subsequent revision of well-fixed components. © 2013 Elsevier Inc.
Gilmore M.L.,New England Baptist Hospital |
Wolfe D.J.,Brigham and Women's Hospital |
Wolfe D.J.,Harvard University
General Hospital Psychiatry | Year: 2013
Objective: The objective was to examine whether prophylactic treatment with antipsychotics can decrease the incidence and severity of postsurgical delirium. Method: A meta-analysis of existing trials comparing delirium incidence between patients given prophylactic antipsychotic and placebo was performed. Secondary outcomes were total hospital days, total days of delirium and severity. Pooled odds ratios (ORs) and mean differences were calculated using a random-effects model. Results: Five randomized placebo-controlled trials comprising a total of 1491 patients were included. In the pooled analysis, prophylactic antipsychotic administration showed a reduction in delirium incidence (OR: 0.42; 95% confidence interval (CI): 0.24, 0.74). Among the studies reporting other outcomes, patients receiving antipsychotics prophylactically showed no differences in total hospital days (0.1; 95% CI: - 0.73, 0.94), days of delirium (- 1.17; 95% CI: - 5.22, 2.88) or delirium severity (- 1.02; 95% CI: - 6.81, 4.76). Conclusions: Prophylactic antipsychotic treatment in surgical patients modestly decreases the incidence of delirium, but not the length of hospital stay, duration of delirium or its severity. Given the modest protective effect of antipsychotics and their potential adverse reactions, there is insufficient evidence to support its universal use as a preventive agent, though potential benefit may be seen in populations at high risk of developing delirium. © 2013 Elsevier Inc.
Nandi S.,New England Baptist Hospital
The journal of knee surgery | Year: 2012
We report herein deep medial collateral ligament (MCL) tear of the knee with application of valgus stress during arthroscopic partial medial meniscectomy. With symptomatic treatment only, the patient went on to heal this injury without incident and recovered in an expected fashion from arthroscopic surgery. There is no earlier report in the literature of deep MCL tear during knee arthroscopy. Awareness of this entity, its consequences, and optimal management are essential as arthroscopic partial meniscectomy is the most common surgery performed by orthopedic surgeons.
Gardiner A.,New England Baptist Hospital
The American journal of sports medicine | Year: 2010
Osteotomies have a role in the active patient with degenerative joint disease of the medial or lateral knee who, for reasons of age or activity level, is not yet a good candidate for prosthetic arthroplasty. Recognition and treatment of malalignment associated with ligamentous instability is essential if long-term good outcomes are to be expected from ligamentous reconstruction. Also, treatment of concomitant malalignment and the unloading of the operative site is now recognized as an important adjunct to any cartilage-preserving surgery. This review examines the use of osteotomies about the knee in the athletic patient. Indications, contraindications, preoperative planning, surgical techniques, and complications are reviewed.
Antonelli M.T.,New England Baptist Hospital
Journal of healthcare risk management : the journal of the American Society for Healthcare Risk Management | Year: 2013
A successful procedural sedation program requires a robust institutional policy backed by a solid educational program and an administrative structure. Given the nature of the services provided, combined with the growth in complexity of both patients and procedures, sedation presents a potential liability for both the provider and the institution. A sedation program is built with a multidisciplinary team of experts representing all stakeholders: healthcare providers, risk and quality improvement managers, and facility administration. An institutional procedural sedation policy should be based on nationally and state recognized practice requirements and guidelines. Clinical care must be supported with a robust risk and quality structure built within the program to ensure best practice at the point of care. © 2013 American Society for Healthcare Risk Management of the American Hospital Association.